ResMed reported robust earnings for the second quarter of fiscal 2025, surpassing expectations and showcasing strong growth ...
Due to its significant market share and high gross margins in a structurally growing industry, ResMed has posted an average return on invested capital, or ROIC, of 20% over the last decade. We ...
In the wake of the U.S. Food and Drug Administration’s approval of Zepbound to treat moderate to severe obstructive sleep ...
ResMed stock is down today, even though the maker of CPAPs and other respiratory treatment devices had Street-beating Q2 ...
Stifel Nicolaus analyst Jonathan Block maintained a Hold rating on Resmed (RMD – Research Report) today and set a price target of $250.00. The ...
Investor's Business Daily on MSN10h
ResMed Tumbles As Organic Sales Growth Steps Down. Will These 'Mega Trends' Save It?ResMed stock tumbled Friday after organic sales growth slowed somewhat in the second fiscal quarter. But one analyst remained upbeat on the "mega trends" driving the CPAP maker.Please watch the video ...
CEO Michael Farrell reported 10% global revenue growth, driven by demand across the sleep health, breathing health, and residential care software portfolios. Device sales, including AirSense 10 and ...
ResMed Inc. RMD has witnessed strong momentum in the past year. Shares of the company have risen 37.8% compared with 10.7% growth of the industry during the same time frame. The S&P 500 composite ...
Analysts at Catapult Wealth are positive on sleep treatment company ResMed and think it could be an ASX 200 share to buy. Catapult Wealth's analysts have been pleased with ResMed's performance in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback